The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index; 5 of the 13 sources its claims cite were checked for support.
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Open accessAbstract
A library of drugs that are in clinical trials or use was screened for inhibitors of hypoxia-inducible factor 1 (HIF-1). Twenty drugs inhibited HIF-1-dependent gene transcription by >88% at a concentration of 0.4 microM. Eleven of these drugs were cardiac glycosides, including digoxin, ouabain, and proscillaridin A, which inhibited HIF-1alpha protein synthesis and expression of HIF-1 target genes in cancer cells. Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within one week. Enforced expression of HIF-1alpha by transfection was not inhibited by digoxin, and xenografts derived from these cells were resistant to the anti-tumor effects of digoxin, demonstrating that HIF-1 is a critical target of digoxin for cancer therapy.
Overview
CoChat Summary
TL;DR
A screen of 3,120 clinically used or trial drugs identified cardiac glycosides, including digoxin, as potent inhibitors of HIF-1α protein synthesis. Digoxin blocked HIF-1 target gene expression and inhibited tumor xenograft growth, with resistance in cells expressing HIF-1α from a transfected vector lacking HIF-1α mRNA untranslated regions.
Key findings
- In a Hep3B-c1 reporter screen, 336 of 3,120 drugs reduced hypoxia-induced firefly/Renilla luciferase activity by ≥50% at 10 µM; after re-screening, the top 20 drugs caused ≥88% inhibition at 0.4 µM, and 11 of these 20 were cardiac glycosides, including digoxin, ouabain, and proscillaridin A.
- Cardiac glycosides inhibited hypoxia-induced HIF-1α and HIF-2α protein expression at concentrations ≥50 nM and decreased mRNA levels of HIF-1 target genes HK1, HK2, and GLUT1 at 1% O2, without inhibiting HIF-1α mRNA.
- Digoxin inhibited HIF-1α protein synthesis independently of the PHD-VHL-proteasome pathway, mTOR/RPS6, Na+/K+ ATPase α1, and topoisomerases; pulse-labeling showed digoxin reduced de novo HIF-1α synthesis by 73% while overall protein synthesis was inhibited by only 19%.
- In SCID mouse xenografts, daily i.p. digoxin at 0.5 or 2 mg/kg inhibited P493-Myc tumor growth dose-dependently; 2 mg/kg inhibited PC3 tumor growth, and delayed treatment of established tumors (mean volume 100 mm3) caused growth arrest within 7 days. PC3-CA5 xenografts expressing constitutively active HIF-1α were resistant to digoxin’s anti-tumor effect.
Methods
- Cell-based screen using Hep3B-c1 cells stably transfected with an HRE-driven firefly luciferase reporter and a constitutive Renilla luciferase reporter; the Hopkins Drug Library of 3,120 FDA-approved or phase II drugs was screened at 10 µM, then re-screened at 2 µM and 0.4 µM.
- Mechanistic assays included immunoblotting for HIF-1α/HIF-2α, quantitative real-time RT-PCR for HIF-1 target mRNAs, [35S]methionine/cysteine pulse-labeling with HIF-1α immunoprecipitation, shRNA knockdown of Na+/K+ ATPase α1 and topoisomerases, flow cytometry, and annexin V staining.
- In vivo studies used SCID mice bearing P493-Myc, PC3-EV, or PC3-CA5 xenografts; digoxin was administered by daily intraperitoneal injection, with tumor volume, body weight, tumor HIF-1α protein, and HIF-1 target gene mRNAs assessed.
Limitations
- The paper states that digoxin has both HIF-1α-dependent and HIF-1α-independent effects on cell growth, based on PC3-CA5 cells growing similarly to vehicle-treated PC3-EV cells.
- Evident from the text: the mechanistic and in vivo work relies on specific cell lines and SCID mouse xenograft models, with no human clinical outcomes reported.
- The provided text is truncated before the end of the Discussion, so any additional limitations stated there are not available.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 4 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIF-1 also controls the expression of genes involved in tumor cell immor- talization, stem cell maintenance/de-differentiation, genetic in- stability, autocrine growth, invasion/metastasis, and treatment failure (6, 7).”
What the sources say
- Not checked — no full text of the sourcecites [6] source
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Figure 3 caption (Angiogenesis section; page not provided) says HIF-regulated genes contribute to proliferation, invasion, and metastasis, and the Differentiation discussion links HIF signaling to an undifferentiated state. But the review does not establish that HIF-1 controls genes for every listed outcome: it attributes direct Oct4 regulation to HIF-2, does not substantiate immortalization or genetic instability, and describes HIF-1’s effects on radiotherapy response as mixed rather than simply causing treatment failure. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Digitoxin inhibited the development of skin pap- illomas in mice treated with dimethylbenzanthracene and tetra- decanoylphorbol ester (34).”
What the sources say
- Supportedcites [34] source
The Results and Discussion (p. 1) report that digitoxin delayed skin papilloma formation and reduced both the proportion of mice bearing papillomas and the average number per mouse. The figure caption on the same page identifies DMBA as the initiator and TPA as the promoter. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The growth of digoxin-treated PC3-CA5 cells was similar to that of vehicle-treated PC3-EV cells.”
§ 4 h pretreatment > 1.00 0.31 0.270.12
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When Hep3B-c1 cells were cultured under hypoxic conditions (1% O2), the ratio of firefly/Renilla luciferase activity was ten-fold higher than when the cells were cultured under nonhy- poxic conditions (20% O2) for 24 h (Fig. 1B).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were obtained in Hep3B cells treated with 100 nM digoxin (Fig. 1G).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 27 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, pharmacologic depletion of HIF1α by small molecules PX478 and Digoxin41,42 also produced similar results in T and NK cells (Fig. 4g, h and Fig. S5f, g, h).”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Digoxin, which is currently passing phase I clinical trials, was reported to inhibit established tumor xenografts with no effect on the growth of constitutively expressing HIF-1 xenografts.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vivo, digoxin inhibits tumor growth and suppresses lung metastasis in orthotopic breast cancer models [295,297].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In HepB cells, these agents reduced both HIF-1α and HIF-2α protein levels without altering HIF1A mRNA, indicating post-transcriptional regulation [295].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredIn the citing paper
“One significant hurdle for the use of these compounds, however, is the lack of specificity of these compounds for specific blockade of HIF (such as digoxin, acriflavine, and 17-AAG) identified to date [124–126].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [125]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“Under normoxic conditions, HIF-1 is hydroxylated on proline residue 564 and/or 402 by proline hydroxylase domain protein 2 (PHD2), which is required for the binding of the von Hippel-Lindau protein (VHL), the recognition subunit of an E3 ubiquitin-protein ligase that targets HIF-1 for proteasomal degradation (10).”
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
(1999) · PubMed · Cited by 2,204
Self-citationPurification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Self-citationRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Self-citationTalks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Cited by
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Self-citationControl of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595
“Other transcription factors have been identified to contribute to the induction of IL-17A in TH17- polarized cells: Runx1 (Zhang et al., 2008), BATF (Schraml et al.”
Self-citationHypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
“Drugs that inhibit the translation of HIF-1α mRNA into protein include: (i) mTOR inhibitors, such as rapamycin, temsirolimus (CCI-779), and everolimus (RAD-001) [50]; (ii) cardiac glycosides, such as digoxin [51], which have been used for decades to treat heart disease; (iii) microtubule targeting agents, such as 2-me…”
BackgroundSelf-citation
Metadata
- Authors
- Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O., & Semenza, G. L.
- Affiliations
- Johns Hopkins University (US)
- Department of Oncology,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-12-16
- Volume
- 105
- Issue
- 50
- Pages
- 19579-19586
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2604945
- OpenAlex
- W2135664375
- Semantic Scholar
- ad3fa6ccad907da0a52a0b821d2be70006a9b6fd
- Cited by
- 624
- References
- 40
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 23 · 2023: 24 · 2022: 35 · 2021: 39 · 2020: 38 · 2019: 34 · 2018: 34 · 2017: 50 · 2016: 42 · 2015: 37 · 2014: 52 · 2013: 57 · 2012: 38
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Flight Attendant Medical Research Institute
- Johns Hopkins University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- digoxin, cardiac glycosides, HIF-1α, HIF-1, tumor growth inhibition, drug screening, ouabain, proscillaridin A, tumor xenografts, cancer therapy
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Cardiac Glycosides, Digoxin, Humans, Transcription, Genetic, Transfection, Protein Biosynthesis, Mice, SCID, Genes, Reporter, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Luciferases, Firefly, Mice, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. https://app.cochat.ai/papers/10.1073/pnas.0809763105
- The paper
- Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O., & Semenza, G. L. (2008). Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0809763105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.